With the outlicensing of our HSV-2 vaccine program to Eurocine Vaccines (Sweden) Redbiotec has achieved one of its biggest goals for the business year 2022. Redbiotec keeps its focus on the development of relevant proteins for biopharma and food industry.

https://www.eurocine-vaccines.com/eurocine-vaccines-expands-its-portfolio-with-a-therapeutic-hsv-2-vaccine-candidate/